Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons
Abstract
:1. Introduction
2. HTLV-1 Infected Subjects’ Immunogenetic Profile
2.1. Human Leukocyte Antigen (HLA) and KIR Genes
2.2. Cytokines Genes
2.3. Apoptosis Genes
2.4. Mannose Binding Lectin Gene
3. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Gotuzzo, E.; Arango, C.; de Queiroz-Campos, A.; Istúriz, R.E. Human T-cell lymphotropic virus-I in Latin America. Infect. Dis. Clin. N. Am. 2000, 14, 211–239. [Google Scholar] [CrossRef]
- Gessain, A.; Cassar, O. Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 2012, 3, 388. [Google Scholar] [CrossRef]
- Eusebio-Ponce, E.; Candel, F.J.; Anguita, E. Human T-cell lymphotropic virus type 1 and associated diseases in Latin America. Trop. Med. Int. Health 2019, 24, 934–953. [Google Scholar] [CrossRef]
- Bangham, C.R. The immune response to HTLV-I. Curr. Opin. Immunol. 2000, 12, 397–402. [Google Scholar] [CrossRef]
- Araujo, A.Q. Update on neurological manifestations of HTLV-1 infection. Curr. Infect. Dis. Rep. 2015, 17, 459. [Google Scholar] [CrossRef]
- Bangham, C.R.M. Human T cell leukemia virus type 1: Persistence and pathogenesis. Annu. Rev. Immunol. 2018, 36, 43–71. [Google Scholar] [CrossRef]
- Osame, M.; Usuku, K.; Izumo, S.; Ijichi, N.; Amitani, H.; Igata, A.; Matsumoto, M.; Tara, M. Htlv-I associated myelopathy, a new clinical entity. Lancet 1986, 327, 1031–1032. [Google Scholar] [CrossRef]
- Varandas, C.M.N.; da Silva, J.L.S.; Primo, J.R.L.; de Oliveira, M.; Moreno-Carvalho, O.; Farre, L.; Bittencourt, A.L. Early juvenile human T-cell lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis: Study of 25 patients. Clin. Infect. Dis. 2018, 67, 1427–1433. [Google Scholar] [CrossRef]
- Bucher, B.; Poupard, J.A.; Vernant, J.C.; DeFreitas, E.C. Tropical neuromyelopathies and retroviruses: A review. Rev. Infect. Dis. 1990, 12, 890–899. [Google Scholar] [CrossRef]
- Maloney, E.M.; Yamano, Y.; Vanveldhuisen, P.C.; Sawada, T.; Kim, N.; Cranston, B.; Hanchard, B.; Jacobson, S.; Hisada, M. Natural history of viral markers in children infected with human T lymphotropic virus type I in Jamaica. J. Infect. Dis. 2006, 194, 552–560. [Google Scholar] [CrossRef]
- Cook, L.B.; Melamed, A.; Demontis, M.A.; Laydon, D.J.; Fox, J.M.; Tosswill, J.H.; de Freitas, D.; Price, A.D.; Medcalf, J.F.; Martin, F.; et al. Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients. Retrovirology 2016, 13, 3. [Google Scholar] [CrossRef]
- Kulkarni, A.; Bangham, C.R.M. HTLV-1: Regulating the balance between proviral latency and reactivation. Front. Microbiol. 2018, 9, 449. [Google Scholar] [CrossRef]
- Matsuura, E.; Kubota, R.; Tanaka, Y.; Takashima, H.; Izumo, S. Visualization of HTLV-1-specific cytotoxic T lymphocytes in the spinal cords of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J. Neuropathol. Exp. Neurol. 2015, 74, 2–14. [Google Scholar] [CrossRef]
- Champs, A.P.S.; Passos, V.M.D.A.; Carvalho, G.; Barreto, S.M.; Meirelles, C.; Caramelli, P. Cognitive impairment in HTLV-1-associated myelopathy, proviral load and inflammatory markers. Int. J. Infect. Dis. 2019, 84, 121–126. [Google Scholar] [CrossRef] [Green Version]
- Bangham, C.R.; Osame, M. Cellular immune response to HTLV-1. Oncogene 2005, 24, 6035–6046. [Google Scholar] [CrossRef] [Green Version]
- Satou, Y.; Matsuoka, M. HTLV-1 and the host immune system: How the virus disrupts immune regulation, leading to HTLV-1 associated diseases. J. Clin. Exp. Hematopathol. 2010, 50, 1–8. [Google Scholar] [CrossRef]
- Takatsuki, K. Discovery of adult T-cell leukemia. Retrovirology 2005, 2, 16. [Google Scholar] [CrossRef]
- Sugimoto, M.; Nakashima, H.; Watanabe, S.; Uyama, E.; Tanaka, F.; Ando, M.; Araki, S.; Kawasaki, S. T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 1987, 330, 1220. [Google Scholar] [CrossRef]
- Belrose, G.; Gross, A.; Olindo, S.; Lezin, A.; Dueymes, M.; Komla-Soukha, I.; Smadja, D.; Tanaka, Y.; Willems, L.; Mesnard, J.M.; et al. Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes. Blood 2011, 118, 2483–2491. [Google Scholar] [CrossRef]
- Baratella, M.; Forlani, G.; Accolla, R.S. HTLV-1 HBZ viral protein: A key player in HTLV-1 mediated diseases. Front. Microbiol. 2017, 8, 2615. [Google Scholar] [CrossRef]
- Nakao, K.; Abematsu, N.; Sakamoto, T. Systemic diseases in patients with HTLV-1-associated uveitis. Br. J. Ophthalmol. 2018, 102, 373–376. [Google Scholar] [CrossRef]
- Barmak, K.; Harhaj, E.; Grant, C.; Alefantis, T.; Wigdahl, B. Human T cell leukemia virus type I-induced disease: Pathways to cancer and neurodegeneration. Virology 2003, 308, 1–12. [Google Scholar] [CrossRef]
- Kannagi, M.; Hasegawa, A.; Takamori, A.; Kinpara, S.; Utsunomiya, A. The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Front. Microbiol. 2012, 3, 323. [Google Scholar] [CrossRef] [Green Version]
- Sonoda, S.; Fujiyoshi, T.; Yashiki, S. Immunogenetics of HTLV-I/II and associated diseases. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 13, S119–S123. [Google Scholar] [CrossRef]
- Manns, A.; Hanchard, B.; Morgan, O.S.; Wilks, R.; Cranston, B.; Nam, J.M.; Blank, M.; Kuwayama, M.; Yashiki, S.; Fujiyoshi, T.; et al. Human leukocyte antigen class II alleles associated with human T-cell lymphotropic virus type I infection and adult T-cell leukemia/lymphoma in a black population. J. Natl. Cancer Inst. 1998, 90, 617–622. [Google Scholar] [CrossRef]
- Jeffery, K.J.; Usuku, K.; Hall, S.E.; Matsumoto, W.; Taylor, G.P.; Procter, J.; Bunce, M.; Ogg, G.S.; Welsh, K.I.; Weber, J.N.; et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc. Natl. Acad. Sci. USA 1999, 96, 3848–3853. [Google Scholar] [CrossRef] [Green Version]
- Jeffery, K.J.; Siddiqui, A.A.; Bunce, M.; Lloyd, A.L.; Vine, A.M.; Witkover, A.D.; Izumo, S.; Usuku, K.; Welsh, K.I.; Osame, M.; et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J. Immunol. 2000, 165, 7278–7284. [Google Scholar] [CrossRef]
- Johnson, J.M.; Nicot, C.; Fullen, J.; Ciminale, V.; Casareto, L.; Mulloy, J.C.; Jacobson, S.; Franchini, G. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J. Virol. 2001, 75, 6086–6094. [Google Scholar] [CrossRef]
- Seki, N.; Yamaguchi, K.; Yamada, A.; Kamizono, S.; Sugita, S.; Taguchi, C.; Matsuoka, M.; Matsumoto, H.; Nishizaka, S.; Itoh, K.; et al. Polymorphism of the 5′-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. J. Infect. Dis. 1999, 180, 880–883. [Google Scholar] [CrossRef]
- Nishimura, M.; Maeda, M.; Matsuoka, M.; Mine, H.; Saji, H.; Matsui, M.; Kuroda, Y.; Kawakami, H.; Uchiyama, T. Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-α, and HLA-DRB1 gene polymorphisms in human T-Cell lymphotropic virus type I associated myelopathy. Hum. Immunol. 2000, 61, 1262–1269. [Google Scholar] [CrossRef]
- Furukawa, Y.; Kubota, R.; Tara, M.; Izumo, S.; Osame, M. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001, 97, 987–993. [Google Scholar] [CrossRef] [Green Version]
- Yashiki, S.; Fujiyoshi, T.; Arima, N.; Osame, M.; Yoshinaga, M.; Nagata, Y.; Tara, M.; Nomura, K.; Utsunomiya, A.; Hanada, S.; et al. HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: The limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes. AIDS Res. Hum. Retrovir. 2001, 17, 1047–1061. [Google Scholar] [CrossRef]
- Sabouri, A.H.; Saito, M.; Usuku, K.; Bajestan, S.N.; Mahmoudi, M.; Forughipour, M.; Sabouri, Z.; Abbaspour, Z.; Goharjoo, M.E.; Khayami, E.; et al. Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J. Gen. Virol. 2005, 86 Pt 3, 773–781. [Google Scholar] [CrossRef]
- Goedert, J.J.; Li, H.C.; Gao, X.J.; Chatterjee, N.; Sonoda, S.; Biggar, R.J.; Cranston, B.; Kim, N.; Carrington, M.; Morgan, O.; et al. Risk of human T-lymphotropic virus type I-associated diseases in Jamaica with common HLA types. Int. J. Cancer 2007, 121, 1092–1097. [Google Scholar] [CrossRef]
- Rafatpanah, H.; Pravica, V.; Faridhosseini, R.; Tabatabaei, A.; Ollier, W.; Poulton, K.; Thomson, W.; Hutchinson, I. Association between HLA-DRB1*01 and HLA-Cw*08 and outcome following HTLV-I infection. Iran. J. Immunol. 2007, 4, 94–100. [Google Scholar]
- Macnamara, A.; Rowan, A.; Hilburn, S.; Kadolsky, U.; Fujiwara, H.; Suemori, K.; Yasukawa, M.; Taylor, G.; Bangham, C.R.; Asquith, B. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog. 2010, 6, e1001117. [Google Scholar] [CrossRef]
- Talledo, M.; Lopez, G.; Huyghe, J.R.; Verdonck, K.; Gonzalez, E.; Clark, D.; Senitzer, D.; Vanham, G.; Gotuzzo, E.; Van Camp, G.; et al. Role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen-C group in susceptibility to human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis in Peru. Hum. Immunol. 2010, 71, 804–808. [Google Scholar] [CrossRef]
- Haddad, R.; Alves, D.C.C.; Rocha-Junior, M.C.; Azevedo, R.; Pombo-de-Oliveira, M.S.; Takayanagui, O.M.; Donadi, E.A.; Covas, D.T.; Kashima, S. HLA-G 14-bp insertion/deletion polymorphism is a risk factor for HTLV-1 infection. AIDS Res. Hum. Retrovir. 2011, 27, 283–288. [Google Scholar] [CrossRef]
- Treviño, A.; Vicario, J.L.; Lopez, M.; Parra, P.; Benito, R.; de Lejarazu, R.O.; Ramos, J.M.; Del Romero, J.; de Mendoza, C.; Soriano, V. Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. J. Neurol. 2013, 260, 2551–2555. [Google Scholar] [CrossRef]
- Taghaddosi, M.; Rezaee, S.A.; Rafatpanah, H.; Rajaei, T.; Hosseini, R.F.; Narges, V. Association between HLA class I alleles and proviral load in HTLV-I associated myelopathy/tropical spastic paraperesis (HAM/TSP) patients in Iranian population. Iran. J. Basic Med. Sci. 2013, 16, 264–267. [Google Scholar]
- Cilião, A.D.C.; Haddad, R.; Rocha-Junior, M.C.; Wagatsuma, V.M.D.D.; Martelli-Palomino, G.; Marques, A.A.; Takayanagui, O.M.; Covas, D.T.; Kashima, S.; Donadi, E.A. HLA-G 3′-untranslated region polymorphisms are associated with HTLV-1 infection, proviral load and HTLV-associated myelopathy/tropical spastic paraparesis development. J. Gen. Virol. 2016, 97, 2742–2752. [Google Scholar] [CrossRef]
- Tarokhian, H.; Taghadosi, M.; Rafatpanah, H.; Rajaei, T.; Azarpazhooh, M.R.; Valizadeh, N.; Rezaee, S.A.R. The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis. Virus Res. 2017, 228, 1–6. [Google Scholar] [CrossRef]
- Assone, T.; Malta, F.M.; Bakkour, S.; Montalvo, L.; Paiva, A.M.; Smid, J.; de Oliveira, A.C.P.; de Toledo Gonçalves, F.; do Carmo Luiz, O.; Fonseca, L.A.M.; et al. Polymorphisms in HLA-C and KIR alleles are not associated with HAM/TSP risk in HTLV-1-infected subjects. Virus Res. 2018, 244, 71–74. [Google Scholar] [CrossRef]
- Boelen, L.; Debebe, B.; Silveira, M.; Salam, A.; Makinde, J.; Roberts, C.H.; Wang, E.C.Y.; Frater, J.; Gilmour, J.; Twigger, K.; et al. Inhibitory killer cell immunoglobulin-like receptors strengthen CD8(+) T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci. Immunol. 2018, 3, eaao2892. [Google Scholar] [CrossRef]
- Al Basatena, N.K.S.; Macnamara, A.; Vine, A.M.; Thio, C.L.; Astemborski, J.; Usuku, K.; Osame, M.; Kirk, G.D.; Donfield, S.M.; Goedert, J.J.; et al. KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog. 2011, 7, e1002270. [Google Scholar] [CrossRef]
- O’Connor, G.M.; Al Basatena, N.K.S.; Olavarria, V.; MacNamara, A.; Vine, A.; Ying, Q.; Hisada, M.; Galvao-Castro, B.; Asquith, B.; McVicar, D.W. In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection. Hum. Immunol. 2012, 73, 783–787. [Google Scholar] [CrossRef]
- Nose, H.; Kubota, R.; Seth, N.P.; Goon, P.K.; Tanaka, Y.; Izumo, S.; Usuku, K.; Ohara, Y.; Wucherpfennig, K.W.; Bangham, C.R.; et al. Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide. J. Infect. Dis. 2007, 196, 1761–1772. [Google Scholar] [CrossRef]
- Saito, M.; Matsuzaki, T.; Satou, Y.; Yasunaga, J.; Saito, K.; Arimura, K.; Matsuoka, M.; Ohara, Y. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2009, 6, 19. [Google Scholar] [CrossRef]
- Campbell, K.S.; Purdy, A.K. Structure/function of human killer cell immunoglobulin-like receptors: Lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011, 132, 315–325. [Google Scholar] [CrossRef]
- Parham, P. The genetic and evolutionary balances in human NK cell receptor diversity. Semin. Immunol. 2008, 20, 311–316. [Google Scholar] [CrossRef] [Green Version]
- Moesta, A.K.; Norman, P.J.; Yawata, M.; Yawata, N.; Gleimer, M.; Parham, P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 2008, 180, 3969–3979. [Google Scholar] [CrossRef]
- Nishimura, M.; Matsuoka, M.; Maeda, M.; Mizuta, I.; Mita, S.; Uchino, M.; Matsui, M.; Kuroda, Y.; Kawakami, H.; Kaji, R.; et al. Association between interleukin-6 gene polymorphism and human T-cell leukemia virus type I associated myelopathy. Hum. Immunol. 2002, 63, 696–700. [Google Scholar] [CrossRef]
- Neco, H.; Teixeira, V.G.S.; Trindade, A.C.L.; Magalhaes, P.M.R.; Lorena, V.M.B.; Vasconcelos, L.R.; Moura, P.; Morais, C.N.L. IL17A polymorphism is not associated with human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis. Viral Immunol. 2017, 30, 298–301. [Google Scholar] [CrossRef]
- Queiroz, M.A.F.; Azevedo, V.N.; Amoras, E.; Moura, T.C.F.; Ishak, M.O.G.; Ishak, R.; Vallinoto, A.C.R.; Feitosa, R.N.M. IFNG +874A/T polymorphism among asymptomatic HTLV-1-infected individuals is potentially related to a worse prognosis. Front. Microbiol. 2018, 9, 795. [Google Scholar] [CrossRef]
- Rocha-Junior, M.C.; Haddad, R.; Cilião Alves, D.C.; de Deus Wagatsuma, V.M.; Mendes-Junior, C.T.; Deghaide, N.H.; Takayanagui, O.M.; Covas, D.T.; Donadi, E.A.; Kashima, S. Interleukin-18 and interferon-gamma polymorphisms are implicated on proviral load and susceptibility to human T-lymphotropic virus type 1 infection. Tissue Antigens 2012, 80, 143–150. [Google Scholar] [CrossRef]
- Schor, D.; Porto, L.C.; Roma, E.H.; Quintana, M.S.B.; Fabricio-Silva, G.M.; Bonecini-Almeida, M.G.; Araujo, A.Q.; Andrada-Serpa, M.J. Lack of association between single-nucleotide polymorphisms of pro- and anti-inflammatory cytokines and HTLV-1-associated myelopathy/tropical spastic paraparesis development in patients from Rio de Janeiro, Brazil. BMC Infect. Dis. 2018, 18, 593. [Google Scholar] [CrossRef]
- Tsukasaki, K.; Miller, C.W.; Kubota, T.; Takeuchi, S.; Fujimoto, T.; Ikeda, S.; Tomonaga, M.; Koeffler, H.P. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res. 2001, 61, 3770–3774. [Google Scholar]
- Kairupan, T.S.; Ibusuki, R.; Kheradmand, M.; Sagara, Y.; Mantjoro, E.M.; Nindita, Y.; Niimura, H.; Kuwabara, K.; Ogawa, S.; Tsumematsu-Nakahata, N.; et al. Interactions between inflammatory gene polymorphisms and HTLV-I infection for total death, incidence of cancer, and atherosclerosis-related diseases among the Japanese population. J. Epidemiol. 2017, 27, 420–427. [Google Scholar] [CrossRef]
- Sabouri, A.H.; Saito, M.; Lloyd, A.L.; Vine, A.M.; Witkover, A.W.; Furukawa, Y.; Izumo, S.; Arimura, K.; Marshall, S.E.; Usuku, K.; et al. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 2004, 190, 1279–1285. [Google Scholar] [CrossRef]
- Gadelha, S.R.; Alcantara, L.C.J.; Costa, G.C.; Acosta, A.X.; Rios, D.; Kashima, S.; Covas, D.T.; Galvao-Castro, B. Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals. J. Med. Virol. 2008, 80, 2141–2146. [Google Scholar] [CrossRef]
- Shirdel, A.; Azarpazhooh, M.R.; Sahebari, M.; Ghanbari, M.; Mirfeizi, S.Z.; Hutchinson, I.; Ziaee, A.; Rafatpanah, H. Association of IL-10 gene polymorphisms and human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in North-East of Iran (Mashhad). Iran. J. Basic Med. Sci. 2013, 16, 258–263. [Google Scholar] [PubMed]
- Braz, M.; Oliveira, J.M.; Rego, J.L.; Carvalho, E.M.; Santos, S.M.B.; Castellucci, L.C. Polymorphism in the interleukin-10 gene is associated with overactive bladder phenotype associated with HTLV-1 infection. Rev. Soc. Bras. Med. Trop. 2019, 52, e20180481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kamihira, S.; Usui, T.; Ichikawa, T.; Uno, N.; Morinaga, Y.; Mori, S.; Nagai, K.; Sasaki, D.; Hasegawa, H.; Yanagihara, K.; et al. Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol. J. 2012, 9, 40. [Google Scholar] [CrossRef] [PubMed]
- Treviño, A.; Lopez, M.; Vispo, E.; Aguilera, A.; Ramos, J.M.; Benito, R.; Roc, L.; Eiros, J.M.; de Mendoza, C.; Soriano, V.; et al. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin. Infect. Dis. 2012, 55, e1–e4. [Google Scholar] [CrossRef] [PubMed]
- Sanabani, S.S.; Nukui, Y.; Pereira, J.; da Costa, A.C.; de Oliveira, A.C.; Pessoa, R.; Leal, F.E.; Segurado, A.C.; Kallas, E.G.; Sabino, E.C. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect. Dis. 2012, 12, 374. [Google Scholar] [CrossRef] [PubMed]
- Assone, T.; de Souza, F.V.; Gaester, K.O.; Fonseca, L.A.; Odo, C.L.; Malta, F.; Pinho, J.R.; Fde, T.G.; Duarte, A.J.; de Oliveira, A.C.; et al. IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers. PLoS Negl. Trop. Dis. 2014, 8, e3199. [Google Scholar] [CrossRef] [PubMed]
- de Sa, K.S.; Santana, B.B.; Ferreira, T.C.D.S.; Sousa, R.C.; Caldas, C.A.; Azevedo, V.N.; Feitosa, R.N.; Machado, L.F.; Ishak, M.D.O.G.; Ishak, R.; et al. IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. Cytokine 2016, 77, 79–87. [Google Scholar] [CrossRef]
- Farre, L.; Bittencourt, A.L.; Silva-Santos, G.; Almeida, A.; Silva, A.C.; Decanine, D.; Soares, G.M.; Alcantara, L.C.; Van Dooren, S.; Galvao-Castro, B.; et al. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J. Leukoc. Biol. 2008, 83, 220–222. [Google Scholar] [CrossRef]
- Vallinoto, A.C.; Santana, B.B.; dos Santos, E.L.; Santo, R.R.; Hermes, R.B.; Sousa, R.C.; Cayres-Vallinoto, I.; Machado, L.F.; Ishak, M.O.; Ishak, R. FAS-670A/G single nucleotide polymorphism may be associated with human T lymphotropic virus-1 infection and clinical evolution to TSP/HAM. Virus Res. 2012, 163, 178–182. [Google Scholar] [CrossRef]
- Rosado, J.; Morales, S.; Lopez, G.; Clark, D.; Verdonck, K.; Gotuzzo, E.; Van Camp, G.; Talledo, M. The FAS-670 AA genotype is associated with high proviral load in peruvian HAM/TSP patients. J. Med. Virol. 2017, 89, 726–731. [Google Scholar] [CrossRef]
- Khouri, R.; Silva-Santos, G.; Dierckx, T.; Menezes, S.M.; Decanine, D.; Theys, K.; Silva, A.C.; Farre, L.; Bittencourt, A.; Mangino, M.; et al. A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and adult T-cell leukemia patients. Oncoimmunology 2018, 7, e1426423. [Google Scholar] [CrossRef] [PubMed]
- Nishimura, M.; Maeda, M.; Yasunaga, J.I.; Kawakami, H.; Kaji, R.; Adachi, A.; Uchiyama, T.; Matsuoka, M. Influence of cytokine and mannose binding protein gene polymorphisms on human t-cell leukemia virus type I (HTLV-I) provirus load in HTLV-I asymptomatic carriers. Hum. Immunol. 2003, 64, 453–457. [Google Scholar] [CrossRef]
- Pontes, G.S.; Tamegao-Lopes, B.; Machado, L.F.; Azevedo, V.N.; Ishak, M.O.; Ishak, R.; Lemos, J.A.; Vallinoto, A.C. Characterization of mannose-binding lectin gene polymorphism among human T-cell lymphotropic virus 1 and 2-infected asymptomatic subjects. Hum. Immunol. 2005, 66, 892–896. [Google Scholar] [CrossRef] [PubMed]
- Alves, A.E.; Hermes, R.B.; Tamegao-Lopes, B.; Machado, L.F.; Azevedo, V.N.; Ishak, M.O.; Ishak, R.; Lemos, J.A.; Vallinoto, A.C. Polymorphism in the promoter region of the mannose-binding lectin gene among human T-cell lymphotropic virus infected subjects. Mem. Inst. Oswaldo Cruz 2007, 102, 991–994. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Montanheiro, P.A.; de Oliveira, A.C.P.; Smid, J.; Fukumori, L.M.; Olah, I.; Duarte, A.J.D.S.; Casseb, J. The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis. Scand. J. Immunol. 2009, 70, 403–407. [Google Scholar] [CrossRef] [PubMed]
- Da Silva, D.G.A.; Sousa, R.C.M.; Gomes, L.F.; Caldas, C.A.M.; Nassiri, R.; Quaresma, J.A.S.; Fuzii, H.T. Correlation between clinical symptoms and peripheral immune response in HAM/TSP. Microb. Pathog. 2016, 92, 72–75. [Google Scholar] [CrossRef]
- Neco, H.; Teixeira, V.; da Trindade, A.C.L.; Magalhaes, P.M.R.; de Lorena, V.M.B.; Castellano, L.R.C.; de Souza, J.R.; Vasconcelos, L.R.; de Moura, P.; de Morais, C.N.L. Mediators go together: High production of CXCL9, CXCL10, IFN-gamma, and TNF-alpha in HTLV-1-associated myelopathy/tropical spastic paraparesis. AIDS Res. Hum. Retrovir. 2017, 33, 1134–1139. [Google Scholar] [CrossRef]
- McLoughlin, R.M.; Jenkins, B.J.; Grail, D.; Williams, A.S.; Fielding, C.A.; Parker, C.R.; Ernst, M.; Topley, N.; Jones, S.A. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. USA 2005, 102, 9589–9594. [Google Scholar] [CrossRef] [Green Version]
- Brown, E.E.; Brown, B.J.; Yeager, M.; Welch, R.; Cranston, B.; Hanchard, B.; Hisada, M. Haplotypes of IL6 and IL10 and susceptibility to human T lymphotropic virus type I infection among children. J. Infect. Dis. 2006, 194, 1565–1569. [Google Scholar] [CrossRef]
- Syedbasha, M.; Egli, A. Interferon lambda: Modulating immunity in infectious diseases. Front. Immunol. 2017, 8, 119. [Google Scholar] [CrossRef]
- Tarokhian, H.; Rahimi, H.; Mosavat, A.; Shirdel, A.; Rafatpanah, H.; Akbarin, M.M.; Bari, A.; Ramezani, S.; Rezaee, S.A. HTLV-1-host interactions on the development of adult T cell leukemia/lymphoma: Virus and host gene expressions. BMC Cancer 2018, 18, 1287. [Google Scholar] [CrossRef] [PubMed]
- Mozhgani, S.H.; Jahantigh, H.R.; Rafatpanah, H.; Valizadeh, N.; Mohammadi, A.; Basharkhah, S.; Rezaee, S.A. Interferon Lambda Family along with HTLV-1 Proviral Load, Tax, and HBZ Implicated in the Pathogenesis of Myelopathy/Tropical Spastic Paraparesis. Neurodegener. Dis. 2018, 18, 150–155. [Google Scholar] [CrossRef] [PubMed]
- Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [Google Scholar] [CrossRef] [PubMed]
- Thorburn, A. Death receptor-induced cell killing. Cell Signal. 2004, 16, 139–144. [Google Scholar] [CrossRef] [PubMed]
- Schwarz, M.; Andrade-Navarro, M.A.; Gross, A. Mitochondrial carriers and pores: Key regulators of the mitochondrial apoptotic program? Apoptosis 2007, 12, 869–876. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nunez, G.; Benedict, M.A.; Hu, Y.; Inohara, N. Caspases: The proteases of the apoptotic pathway. Oncogene 1998, 17, 3237–3245. [Google Scholar] [CrossRef] [PubMed]
- Thornberry, N.A. Caspases: Key mediators of apoptosis. Chem. Biol. 1998, 5, R97–R103. [Google Scholar] [CrossRef]
- Itoh, N.; Yonehara, S.; Ishii, A.; Yonehara, M.; Mizushima, S.I.; Sameshima, M.; Hase, A.; Seto, Y.; Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66, 233–243. [Google Scholar] [CrossRef]
- Oehm, A.; Behrmann, I.; Falk, W.; Pawlita, M.; Maier, G.; Klas, C.; Li-Weber, M.; Richards, S.; Dhein, J.; Trauth, B.C. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992, 267, 10709–10715. [Google Scholar]
- Huang, Q.R.; Morris, D.; Manolios, N. Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997, 34, 577–582. [Google Scholar] [CrossRef]
- Huang, Q.R.; Danis, V.; Lassere, M.; Edmonds, J.; Manolios, N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxf.) 1999, 38, 645–651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bolstad, A.I.; Wargelius, A.; Nakken, B.; Haga, H.J.; Jonsson, R. Fas and Fas ligand gene polymorphisms in primary Sjogren’s syndrome. J. Rheumatol. 2000, 27, 2397–2405. [Google Scholar] [PubMed]
- Pinti, M.; Troiano, L.; Nasi, M.; Moretti, L.; Monterastelli, E.; Mazzacani, A.; Mussi, C.; Ventura, P.; Olivieri, F.; Franceschi, C.; et al. Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: Studies on centenarians. Cell Death Differ. 2002, 9, 431–438. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Wang, L.E.; Sturgis, E.M.; El-Naggar, A.K.; Hong, W.K.; Amos, C.I.; Spitz, M.R.; Wei, Q. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2006, 12, 5596–5602. [Google Scholar] [CrossRef] [PubMed]
- Menezes, S.M.; Leal, F.E.; Dierckx, T.; Khouri, R.; Decanine, D.; Silva-Santos, G.; Schnitman, S.V.; Kruschewsky, R.; Lopez, G.; Alvarez, C.; et al. A fashi lymphoproliferative phenotype reveals non-apoptotic fas signaling in HTLV-1-associated neuroinflammation. Front. Microbiol. 2017, 8, 97. [Google Scholar] [CrossRef] [PubMed]
- Ohya, O.; Tomaru, U.; Yamashita, I.; Kasai, T.; Morita, K.; Ikeda, H.; Wakisaka, A.; Yoshiki, T. HTLV-I induced myeloneuropathy in WKAH rats: Apoptosis and local activation of the HTLV-I pX and TNF-alpha genes implicated in the pathogenesis. Leukemia 1997, 11 (Suppl. 3), 255–257. [Google Scholar]
- Vallinoto, A.C.R.; Santana, B.B.; Queiroz, M.A.F.; da Silva, A.; Cayres-Vallinoto, I.M.V.; da Costa, C.A.; de Sousa, M.S.; Ishak, R. Family aggregation of HTLV-1 infection associated with FAS -670A/G polymorphism: A case report. Front. Microbiol. 2018, 8, 2685. [Google Scholar] [CrossRef]
- Petersen, S.V. The mannan-binding lectin pathway of complement activation: Biology and disease association. Mol. Immunol. 2001, 38, 133–149. [Google Scholar] [CrossRef]
- Nitta, T.; Tanaka, M.; Sun, B.; Hanai, S.; Miwa, M. The genetic background as a determinant of human T-cell leukemia virus type 1 proviral load. Biochem. Biophys. Res. Commun. 2003, 309, 161–165. [Google Scholar] [CrossRef]
- Coelho, A.V.; Brandao, L.A.; Guimaraes, R.L.; Loureiro, P.; Filho, J.L.D.L.; de Alencar, L.C.; Crovella, S.; Segat, L. Mannose binding lectin and mannose binding lectin-associated serine protease-2 genes polymorphisms in human T-lymphotropic virus infection. J. Med. Virol. 2013, 85, 1829–1835. [Google Scholar] [CrossRef]
- Santana, B.B.; da Silva, R.A.; Valentim, C.Y.U.P.A.; Amoras, E.S.G.; Rodrigues, C.M.; de Sousa, M.S.; Goulart, L.R.; Vallinoto, A.C.R. Evaluation of Annexin 1 as a clinical prognosis biomarker in HTLV-1 infection. In: XIV International Symposium on HTLV in Brazil. Rev. Patol. Trop. 2018, 47 (Suppl. 3), 85. [Google Scholar]
Gene | Alleles/Genotype | Country | Method | N | Disease | Association | Reference |
---|---|---|---|---|---|---|---|
HLA | A*26, B*61, and DR9 | Japan | PCR-SSP | 330 | ATLL | Risk | [24] |
A*24 and Cw*01 | ATLL | Protective | |||||
Cw*7, B*7 and DR1 | HAM | Risk | |||||
B*61 and DRB1*0901 | Japan | PCR-SSOPs | 652 | Uveitis | No | [29] | |
A*02 | Japan | PCR-SSP | 433 | HAM | Protective | [26] | |
DRB1*0101 | HAM | Susceptibility | |||||
A*02, Cw*08 | Japan | PCR-SSP | 435 | HAM | Protective | [27] | |
B*5401 | HAM | Susceptibility | |||||
DRB1* 0405, DRB1*09 | Japan | PCR-SSP | 261 | HAM | No | [30] | |
ATLL | No | ||||||
A*02 | Japan | PCR-SSP | 178 | ATLL | Susceptibility | [31] | |
*A26, Cw*08, B*4002, B*4006, and B*4801 | Japan | PCR-SSP ARMS | 599 | ATLL HAM | Susceptibility No | [32] | |
DRB1*0101 | Iran | PCR-SSP | 132 | HAM | Susceptibility | [33] | |
Japan | PCR-SSP | 406 | HAM | Susceptibility | |||
A*02 | Iran | PCR-SSP | 132 | HAM | No | ||
Japan | PCR-SSP | 406 | HAM | No | |||
DRB1*1503 and DQB1*0602 | Jamaica | PCR-SSP PCR-SSO | 195 | HAM | Low risk | [34] | |
A*03 and DQB1*0501 | ATLL | Low risk | |||||
B*15 and B*53 | ATLL | High risk | |||||
DRB1*01 | Iran | PCR-SSP | 142 | HAM | Susceptibility | [35] | |
Cw*08 | Low CTL response | ||||||
A*0201, Cw*0801 | Japan | PCR-SSP | 432 | HAM | Protective | [36] | |
HLA-A*02 and Cw*08 | Peru | PCR-SSP | 165 | HAM | No | [37] | |
HLA-G-14-bp deletion | Brazil | PCR | 150 | HAM ATLL | No | [38] | |
B*07, DRB1*01:01 | Spain | Bead array | 40 | HAM | Susceptibility | [39] | |
A*02, A*24, Cw*08 | Iran | PCR-SSP | 50 | HAM | No | [40] | |
HLA-G 3’-UTR14 bp ins/del | Brazil | PCR | 235 | HAM | Risk for infection | [41] | |
HLA-G 3’-UTR14 bp del/del, +3003TT and +3142CC | HAM | Protective | |||||
HLA-G 3′-UTR +3142C, +3003CT and +3142CC | HAM | Susceptibility | |||||
A*02, A*24, Cw*08, and B*5401 | Iran | PCR | 71 | HAM | No | [42] | |
HLA-C | Brazil | qPCR | 241 | HAM | No | [43] | |
HLA-B*54 | Japan | Mathematical modeling | 392 | HAM | Detrimental effect | [44] | |
HLA-A*02:07, HLA-B*57 and HLA-C*08 | HAM | Protective | |||||
KIR | KIR3DS1 | Peru | PCR-SSP | 165 | HAM | No | [37] |
KIR2DL2 | Japan | PCR-SSP | 402 | HAM | Protective | [45] | |
KIR3DS1 | Jamaica | PCR-SSP | 111 | HAM ATLL | No | [46] | |
Brazil | PCR-SSP | 216 | HAM | No | |||
Japan | PCR-SSP | 402 | HAM | No | |||
KIR2DL2 | Japan | Mathematical modeling | 392 | HAM | Protective | [44] | |
KIR3DL1 | HAM | Detrimental effect | |||||
KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS3 | Brazil | qPCR | 246 | HAM | No | [43] |
Gene | Alleles/Genotype | Country | Method | N | Disease | Association | Reference |
---|---|---|---|---|---|---|---|
LT-α | LT-α*A/G | Japan | PCR-RFLP | 261 | HAM | Susceptibility | [30] |
ATLL | No | ||||||
TNFR2 | TNFR2* 196R | Japan | PCR-SSP | 261 | HAM | Susceptibility | [30] |
ATLL | No | ||||||
IL1-β | −511*1/2 | Japan | PCR-RFLP | 368 | HAM | No | [52] |
IL-17A | −197*G/A | Brazil | qPCR | 116 | HAM | No | [53] |
IFN-γ | +874*A/T | Brazil | qPCR | 453 | HAM | Risk | [54] |
+874*A/T | Brazil | qPCR | 148 | HAM | No | [55] | |
+874*A/T | Brazil | PCR-SSP | 700 | HAM | No | [56] | |
IL-18 | −607*AC | Brazil | qPCR | 148 | HAM | Risk | [55] |
−607*CC | Protective | ||||||
−137*C/G | No | ||||||
TNF-α | −1031*C (T > C) | Japan | PCR-SSOPs | 652 | Uveitis | Risk | [29] |
−863*A (C > A) | Risk | ||||||
−1031*T > C and −863*C/A | Japan | PCR-SSP | 261 | HAM | No | [30] | |
−857*T (C/T) | HAM | Susceptibility | |||||
ATLL | No | ||||||
−857*T (C/T) | Japan | PCR-SSOPs | 151 | ATLL | Risk | [57] | |
−1031TT (T/C) | Japan | qPCR | 2180 | Atherosclerosis | Risk | [58] | |
−380*G/A | Brazil | PCR-SSP | 700 | HAM | No | [56] | |
TGF-β | +10*T/C and +25*G/C | Brazil | PCR-SSP | 700 | HAM | No | [56] |
IL-10 | −592*A (C/A) | Japan | PCR-RFLP | 368 | HAM | No | [52] |
−592*A (C/A) | Japan | PCR-RFLP | 535 | HAM | Low risk | [59] | |
−3575(T/A), −2849 (G/A), −2763 (C/A), −1082 (A/G) and −819 (T/C) | No | ||||||
−592*A (C/A) | Brazil | PCR-RFLP qPCR | 233 | HAM | No | [60] | |
−1082*G/A, −819*C/T and −592*C/A (Haplotype “ATA”) | Iran | ARMS-PCR | 332 | HAM | Susceptibility | [61] | |
819*T/C | Japan | qPCR | 2180 | Atherosclerosis | No | [58] | |
−1082*A/G, −592C/A and −819C/T | Brazil | PCR-SSP | 700 | HAM | No | [56] | |
+4976*A/G, −819*A/G | Brazil | qPCR | 678 | HAM | No | [62] | |
−1082*A (A/G) | Protective | ||||||
IL-6 | −634*G/C | Japan | PCR-RFLP | 368 | HAM | Susceptibility | [52] |
−634*G/C | Brazil | PCR-RFLP qPCR | 233 | HAM | Susceptibility | [60] | |
−174*G/C, −572*G/C and −597*G/A | No | ||||||
−174*G/C | Brazil | PCR-SSP | 700 | HAM | No | [56] | |
IL-28B | rs8099917 *T/G | Japan | PCR and Sequencing | 340 | ATLL | No | [63] |
rs12979860 *C/T | Spain | qPCR | 199 | HAM | Risk | [64] | |
rs12979860 *C/T | Brazil | PCR and Sequencing | 112 | HAM | No | [65] | |
rs8099917 *GG (T > G) | Brazil | qPCR | 229 | HAM | Risk | [66] | |
rs12979860 *CT (C > T) | Risk | ||||||
rs8099917 T/G, rs12979860 C/T and rs8103142 T/C Haplotypes TTG and CTT | Brazil | pPCR | Arthropathy | Susceptibility for infection | [67] | ||
Haplotype TTG | Risk | ||||||
Fas/FasL | −670*AA (A > G) | Brazil | PCR-RFLP | 134 | ATLL | Severity | [68] |
−670*GG (A > G) | Survival | ||||||
−670*AA (A > G) | Brazil | PCR-RFLP | HAM | Risk | [69] | ||
−670*GG (A > G) | Susceptibility for infection | ||||||
−670*AA (A/G) | Peru | PCR Kbiosciences | 216 | HAM | Risk | [70] | |
−844*C/T and −1377*G/A | No | ||||||
−670*A > G | Brazil | PCR-RFLP | 25 | ATLL | ↑Apoptosis | [71] | |
MBL2 | Mbl*B | Japan | PCR-RFLP | 143 | Asymptomatic | ↓PV load | [72] |
Mbl*A and Mbl*D | Brazil | PCR-RFLP | 182 | Asymptomatic | No | [73] | |
Mbl*B | ↑PV load | ||||||
−550*H/L and −221*X/Y LYLX genotype | Brazil | PCR-SSP | 174 | Asymptomatic | Risk for infection | [74] | |
NF-kB1 | 94ATTG ins/del | Japan | qPCR | 2180 | No | [58] | |
GSTM1 | +/− | Japan | PCR-SSOPs | 151 | ATLL | No | [57] |
GSTT1 | +/− | ||||||
CYP1A1 | +/− | ||||||
BCL2 | +/− |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vallinoto, A.C.R.; Cayres-Vallinoto, I.; Freitas Queiroz, M.A.; Ishak, M.d.O.G.; Ishak, R. Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons. Viruses 2019, 11, 974. https://doi.org/10.3390/v11110974
Vallinoto ACR, Cayres-Vallinoto I, Freitas Queiroz MA, Ishak MdOG, Ishak R. Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons. Viruses. 2019; 11(11):974. https://doi.org/10.3390/v11110974
Chicago/Turabian StyleVallinoto, Antonio Carlos Rosário, Izaura Cayres-Vallinoto, Maria Alice Freitas Queiroz, Marluísa de Oliveira Guimarães Ishak, and Ricardo Ishak. 2019. "Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons" Viruses 11, no. 11: 974. https://doi.org/10.3390/v11110974